Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.
Activation of the hedgehog (HH) pathway plays a critical role in the development and continued growth of pancreatic adenocarcinoma (PAC). Cyclopamine, a HH pathway inhibitor, has been shown to suppress PAC cell proliferation in vitro and in vivo. However, the molecular basis of response to cyclopamine has not been fully elucidated nor have genes that predict sensitivity to this compound been identified. To better understand these features of HH pathway inhibition, we evaluated the biological and molecular effects of cyclopamine in vitro. The viability of 9 human PAC cell lines following cyclopamine exposure was determined using MTS assay. Proliferation and induction of apoptosis in treated cells were examined by bromo-deoxyuridine incorporation, caspase activation, and mitochondrial membrane potential. Gene expression before and after cyclopamine treatment was determined using Taqman real-time quantitative polymerase chain reaction (RTQ-PCR) and Taqman low-density array (TLDA). Among the cell lines examined, cyclopamine IC50 values ranged from 8.79 to >30 µM. Response to cyclopamine included reduced cell proliferation and induction of apoptosis with and without mitochondrial membrane depolarization. Regression analysis revealed that GLI3 expression significantly correlated with cyclopamine resistance (r = 0.80; p = 0.0102). Knockdown of GLI3 using siRNAs increased sensitivity to cyclopamine. In addition, GLI3 siRNAs decreased PAC cell viability and reduced expression of genes involved in HH signaling (Patched 1 and GLI1) and cell proliferation, similar to cyclopamine. These effects were not observed in PAC cells with undetectable GLI3 expression. These data suggest that Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.
Steg
Adam
A
Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Amm
Hope M
HM
Novak
Zdenek
Z
Frost
Andra R
AR
Johnson
Martin R
MR
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D001973:Bromodeoxyuridine; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005434:Flow Cytometry; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D051741:Kruppel-Like Transcription Factors / Q000235:genetics / Q000378:metabolism*; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016133:Polymerase Chain Reaction; D034741:RNA, Small Interfering; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D014704:Veratrum Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*; D000074290:Zinc Finger Protein Gli3
D000970:Antineoplastic Agents; C065683:GLI3 protein, human; D053823:Hedgehog Proteins; D051741:Kruppel-Like Transcription Factors; D009419:Nerve Tissue Proteins; D034741:RNA, Small Interfering; D014704:Veratrum Alkaloids; D000074290:Zinc Finger Protein Gli3; D020169:Caspases; D001973:Bromodeoxyuridine; C000541:cyclopamine
Int J Cancer. 2004 Jul 10;110(5):668-76
15146555
Nature. 2003 Oct 23;425(6960):846-51
14520411
Genes Dev. 2002 Nov 1;16(21):2743-8
12414725
Mol Immunol. 2004 Jul;41(6-7):715-25
15220006
Nat Rev Cancer. 2003 Dec;3(12):903-11
14737121
Development. 2005 Jul;132(14):3267-79
15983404
Nature. 2008 Sep 18;455(7211):406-10
18754008
Development. 1999 Jun;126(12):2623-30
10331974
Clin Exp Metastasis. 1992 Jul;10(4):259-66
1319859
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21
12679522
J Clin Oncol. 1998 Jan;16(1):317-23
9440759
Nat Genet. 1997 Mar;15(3):266-8
9054938
Mol Cell Biol. 1990 Oct;10(10):5408-15
2118997
Gastroenterology. 2005 May;128(6):1642-54
15887156
Science. 1998 Jun 5;280(5369):1603-7
9616123
Nature. 1991 Aug 8;352(6335):539-40
1650914
Hum Pathol. 1996 Feb;27(2):119-24
8617452
J Mol Diagn. 2006 Feb;8(1):76-83
16436637
Nature. 2000 Aug 31;406(6799):1005-9
10984056
Cancer Cell. 2004 Sep;6(3):229-40
15380514
Cancer Res. 2004 Oct 15;64(20):7545-52
15492281
Nature. 2004 Oct 7;431(7009):707-12
15361885
Nat Rev Cancer. 2002 Dec;2(12):897-909
12459728
Cancer. 1981 Oct 15;48(8):1705-10
7284971
Cancer Res. 2002 Oct 15;62(20):5867-73
12384550
Anal Biochem. 2000 Feb 15;278(2):175-84
10660460
Science. 2002 Aug 30;297(5586):1559-61
12202832
J Cell Sci. 2002 Dec 1;115(Pt 23):4393-7
12414986
Oncogene. 2007 Jul 5;26(31):4489-98
17297467
Genes Dev. 1992 Dec;6(12B):2635-45
1340474
Nature. 2003 Oct 23;425(6960):851-6
14520413
Cancer Res. 2004 Nov 1;64(21):7724-31
15520176
Diagn Mol Pathol. 2007 Dec;16(4):229-37
18043287
Oncogene. 2008 Oct 20;27(48):6194-206
18931687
Development. 2001 Dec;128(24):5201-12
11748155
Am J Pathol. 1994 Dec;145(6):1547-50
7992857
J S C Med Assoc. 2003 Apr;99(4):79-81
12762152
Cancer Res. 2007 Jul 15;67(14):6981-6
17638910
Curr Oncol Rep. 2003 May;5(3):219-26
12667419
Anal Biochem. 2002 Apr 15;303(2):209-14
11950223
Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17
15803137
Am J Vet Res. 1963 Nov;24:1164-75
14081451
Breast Cancer Res Treat. 2009 Jun;115(3):505-21
18563554
Cancer Cell. 2008 Oct 7;14(4):281-3
18835029
Ann Oncol. 2003 May;14(5):675-92
12702520